ARMGO Pharma (United States)

Recent papers from ARMGO Pharma (United States)

1. Formulation Design of a Hot-melt Extrusion-Based Amorphous Solid Dispersion to Optimize Palatability of Berberine Hydrochloride with In Vitro and In Vivo EvaluationAAPS PharmSciTech · 2026
2. Diabetes treatment by conversion of gut epithelial cells to insulin‐producing cellsJournal of Diabetes Investigation · 2024
3. Rycal S48168 (ARM210) for RYR1-related myopathies: a phase one, open-label, dose-escalation trialEClinicalMedicine · 2024
4. Adrenal insufficiency is a contraindication for omalizumab therapy in mast cell activation disease: risk for serum sicknessNaunyn-Schmiedeberg s Archives of Pharmacology · 2020
5. Evaluation of the Cunningham Panel™ in pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS): Changes in antineuronal antibody titers parallel changes in patient symptomsJournal of Neuroimmunology · 2019
6. Targeting RyR Activity Boosts Antisense Exon 44 and 45 Skipping in Human DMD Skeletal or Cardiac Muscle Culture ModelsMolecular Therapy — Nucleic Acids · 2019
7. Mast cell deposition and activation may be a new explanation for epiploic appendagitisBMJ Case Reports · 2018
8. Population PK Analyses of Ubrogepant (MK‐1602), a CGRP Receptor Antagonist: Enriching In‐Clinic Plasma PK Sampling With Outpatient Dried Blood Spot SamplingThe Journal of Clinical Pharmacology · 2017
9. Reprint of 'Model of unidirectional block formation leading to reentrant ventricular tachycardia in the infarct border zone of postinfarction canine hearts'Computers in Biology and Medicine · 2015
10. Identification of Small Molecules That Selectively Inhibit Diacylglycerol Lipase–α ActivitySLAS DISCOVERY · 2013
11. Virus-Like Particle Vaccine Conferred Complete Protection Against a Lethal Influenza Virus ChallengeViral Immunology · 2005
12. Virus-Like Particle (VLP) Vaccine Conferred Complete Protection against a Lethal Influenza Virus ChallengeViral Immunology · 2005
13. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl–positive human acute leukemia cellsBlood · 2003